Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SR-3306 是一种能够透过血脑屏障的JNK 选择性抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 456 | 现货 | ||
5 mg | ¥ 1,080 | 现货 | ||
10 mg | ¥ 1,660 | 现货 | ||
25 mg | ¥ 3,250 | 现货 | ||
50 mg | ¥ 5,820 | 现货 | ||
100 mg | ¥ 7,860 | 现货 | ||
500 mg | ¥ 15,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,180 | 现货 |
产品描述 | SR-3306 is a potent and highly inhibitor of brain penetrant JNK. |
体外活性 | H9c2 cells treated with H2O2/FeSO4 (100 μM) are ~40% viable, whereas the addition of SR-3306(500 nM) or SR3562(500 nM ) to cells treated with H2O2/FeSO4(100 μM) increases viability to ~90%, and the addition of 10 μM Tat-Sab peptide to cells treated with H2O2/FeSO4 (100 μM) increases viability to ~70% compared with 98% viability in untreated cells [2]. |
体内活性 | SR-3306 (10 mg/kg/day (s.c.) for 14 days) decreases d-amphetamine-induced circling by 87% compared to 6-hydroxydopamine (6-OHDA)-lesioned animals given vehicle. Steady-state brain levels of SR-3306 at day 14 are 347 nM, which is approximately 2-fold higher than the cell-based IC50 for this compound. SR-3306 (10 mg/kg/day (s.c.) for 14 days) administration increases the number of tyrosine hydroxylase immunoreactive (TH+) neurons in the SNpc by 6-fold and reduces the loss of the TH+ terminals in the striatum relative to the corresponding side of 6-OHDA-lesioned rats that receive the only vehicle (p<0.05). Finally, immunohistochemical staining for phospho-c-jun (p-c-jun) reveals that SR-3306 (10 mg/kg/day (s.c.) for 14 days) produces a 2.3-fold reduction of the number of immunoreactive neurons in the substantia nigra pars compacta (SNpc) relative to vehicle-treated rats. In lean mice, intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration of SR-3306 reduces food intake and body weight. SR11935(i.p. and i.c.v.) treatment exert similar anorectic effects as SR3306, which suggests JNK2 or JNK3 mediates aspect of the anorectic effect by pan-JNK inhibition. Furthermore, SR-3306 (daily i.p. injection, 7 days) prevents the increases in food intake and weight gain in lean mice upon high-fat diet feeding, and this injection paradigm reduced high-fat intake and obesity in diet-induced obese mice [1][3]. |
分子量 | 490.56 |
分子式 | C28H26N8O |
CAS No. | 1128096-91-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (254.81 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0385 mL | 10.1924 mL | 20.3849 mL | 50.9622 mL |
5 mM | 0.4077 mL | 2.0385 mL | 4.077 mL | 10.1924 mL | |
10 mM | 0.2038 mL | 1.0192 mL | 2.0385 mL | 5.0962 mL | |
20 mM | 0.1019 mL | 0.5096 mL | 1.0192 mL | 2.5481 mL | |
50 mM | 0.0408 mL | 0.2038 mL | 0.4077 mL | 1.0192 mL | |
100 mM | 0.0204 mL | 0.1019 mL | 0.2038 mL | 0.5096 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SR-3306 1128096-91-2 MAPK JNK SR 3306 Inhibitor SR3306 inhibit inhibitor